🔗 Share this article WHO Raises Alert Over Acute Lack of Obesity Injections Under 10% of individuals who could benefit from obesity jabs such as Wegovy can access them, caution the WHO as it issues its first guidance on the therapies. Given over a billion people worldwide currently living with obesity, it is calling for increased and just access to this class of drugs. Based on estimates, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken. "Our latest guidelines acknowledges that excess weight is a chronic disease that can be treated with thorough and ongoing care," said the agency's head Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and distribution challenges are key obstacles to broad access to the treatments that can assist patients in reducing substantial weight, explains the body. GLP-1 Therapy Scarcity Even in the present best projected scenario, the production of these medications would only suffice for around 100 million people – less than 10% of eligible patients, according to the WHO. The recommendation encourages governments and firms to increase access, by measures such as voluntary licensing. A patent on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in multiple nations in 2026. How Weight-Loss Injections Operate The injections replicate a natural hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so people eat less. Individuals typically see weight reduction after several weeks of beginning the regular doses. Research points to users may regain a significant portion within a year of discontinuing the treatment, because their normal food cravings resume. Being carrying excess weight increases your chance for contracting medical conditions, such as diabetes, heart disease, brain attack, and specific cancers. Excess weight concerns people in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.
Under 10% of individuals who could benefit from obesity jabs such as Wegovy can access them, caution the WHO as it issues its first guidance on the therapies. Given over a billion people worldwide currently living with obesity, it is calling for increased and just access to this class of drugs. Based on estimates, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken. "Our latest guidelines acknowledges that excess weight is a chronic disease that can be treated with thorough and ongoing care," said the agency's head Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and distribution challenges are key obstacles to broad access to the treatments that can assist patients in reducing substantial weight, explains the body. GLP-1 Therapy Scarcity Even in the present best projected scenario, the production of these medications would only suffice for around 100 million people – less than 10% of eligible patients, according to the WHO. The recommendation encourages governments and firms to increase access, by measures such as voluntary licensing. A patent on a key compound – the core ingredient of the drug Wegovy – is scheduled to end in multiple nations in 2026. How Weight-Loss Injections Operate The injections replicate a natural hormone to reduce digestion speed, suppress the appetite and enhance feelings of fullness so people eat less. Individuals typically see weight reduction after several weeks of beginning the regular doses. Research points to users may regain a significant portion within a year of discontinuing the treatment, because their normal food cravings resume. Being carrying excess weight increases your chance for contracting medical conditions, such as diabetes, heart disease, brain attack, and specific cancers. Excess weight concerns people in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.